Home  /  Resource Library  /  Umbralisib, the Once Daily Dual Inhibitor of PI3K and Casein Kinase-1 Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

Umbralisib, the Once Daily Dual Inhibitor of PI3K and Casein Kinase-1 Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial

ASH 2020: Results of a phase II trial investigating Umbralisib for treatment of relapsed indolent lymphomas.